This second of four exclusive episodes explores whether sparsentan can leapfrog renin-angiotensin system (RAS) blockade and how emerging biomarkers may reshape management of IgA nephropathy. Nigwekar: ...

The company completed its submission for FDA review of a supplemental New Drug Application (sNDA) for FILSPARI in FSGS, potentially positioning it as the first approved therapy for this condition. If ...

Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard ...

“As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the ...

The European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing ...

“The European Commission’s standard approval of FILSPARI is a meaningful step forward for people living with IgA nephropathy across Europe,” said Jula Inrig, M.D., chief medical officer of ...

The UK’s MHRA also converts the conditional approval of FILSPARI to standard approval Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European ...

We look forward to continuing working closely with healthcare professionals, patient communities, and regulatory bodies to ensure access to FILSPARI across Europe." The European Commission's ...